Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Lancet HIV. 2019 May;6(5):e283-e296. doi: 10.1016/S2352-3018(19)30034-7. Epub 2019 Apr 2.
BACKGROUND: To achieve reductions in HIV incidence, we need strategies to engage key population at risk for HIV in low-income and middle-income countries. We evaluated the effectiveness of integrated care centres in India that provided single-venue HIV testing, prevention, and treatment services for people who inject drugs (PWID) and men who have sex with men (MSM). METHODS: We did baseline respondent-driven sampling surveys in 27 sites across India, and selected 22 of these (12 PWID and ten MSM) for a cluster randomised trial on the basis of high HIV prevalence and logistical considerations. We used stratified (by PWID and MSM), restricted randomisation to allocate sites to either the integrated care intervention or usual care (11 sites per group). We implemented integrated care centres in 11 cities (six PWID integrated care centres embedded within opioid agonist treatment centres and five MSM centres within government-sponsored health services), with a single integrated care centre per city in all but one city. After a 2-year intervention phase, we did respondent-driven sampling evaluation surveys of target population members who were aged 18 years or older at all sites. The primary outcome was self-reported HIV testing in the previous 12 months (recent testing), determined via the evaluation survey. We used a biometric identification system to estimate integrated care centre exposure (visited an integrated care centre at least once) among evaluation survey participants at intervention sites. This trial is registered with ClinicalTrials.gov, number NCT01686750. FINDINGS: Between Oct 1, 2012, and Dec 19, 2013, we recruited 11 993 PWID and 9997 MSM in the baseline survey and, between Aug, 1 2016, and May 27, 2017, surveyed 11 721 PWID and 10 005 MSM in the evaluation survey using respondent-driven sampling, across the 22 trial sites. During the intervention phase, integrated care centres provided HIV testing for 14 698 unique clients (7630 PWID and 7068 MSM. In the primary population-level analysis, recent HIV testing was 31% higher at integrated care centres than at usual care sites (adjusted prevalence ratio [PR] 1·31, 95% CI 0·95-1·81, p=0·09). Among survey participants at intervention sites, integrated care centre exposure was lower than expected (median exposure 40% at PWID sites and 24% at MSM sites). In intervention sites, survey participants who visited an integrated care centre were more likely to report recent HIV testing than were participants who had not (adjusted PR 3·46, 2·94-4·06). INTERPRETATION: Although integrated care centres increased HIV testing among visitors, our low exposure findings suggest that the scale-up of a single integrated care centre in most cities was insufficient to serve the large PWID and MSM populations. Future work should address the use of population size estimates to guide the dose of combination HIV interventions targeting key populations. FUNDING: US National Institutes of Health and the Elton John AIDS Foundation.
背景:为了降低艾滋病毒的发病率,我们需要制定策略,让处于艾滋病毒感染风险中的关键人群,即低收入和中等收入国家的吸毒者和男男性接触者(MSM)参与进来。我们评估了印度综合关怀中心的有效性,这些中心为吸毒者和 MSM 提供了单一地点的艾滋病毒检测、预防和治疗服务。
方法:我们在印度 27 个地点进行了基线应答者驱动抽样调查,并根据高艾滋病毒流行率和后勤考虑,选择了其中 22 个地点(12 个吸毒者和 10 个 MSM)进行基于群组的随机试验。我们采用分层(按吸毒者和 MSM 分层)、受限随机化的方法,将地点分配到综合关怀干预组或常规护理组(每组 11 个地点)。我们在 11 个城市(6 个吸毒者综合关怀中心嵌入阿片类药物替代治疗中心,5 个 MSM 中心嵌入政府资助的卫生服务)设立了综合关怀中心,除了一个城市外,每个城市都只有一个综合关怀中心。在为期 2 年的干预阶段后,我们对所有年龄在 18 岁或以上的目标人群成员进行了应答者驱动抽样评估调查。主要结果是在过去 12 个月内(最近检测)自我报告的艾滋病毒检测,通过评估调查确定。我们使用生物识别系统来估计评估调查参与者在干预点的综合关怀中心的暴露情况(至少访问过一次综合关怀中心)。这项试验在 ClinicalTrials.gov 上注册,编号为 NCT01686750。
结果:2012 年 10 月 1 日至 2013 年 12 月 19 日,我们在基线调查中招募了 11993 名吸毒者和 9997 名 MSM,并在 2016 年 8 月 1 日至 2017 年 5 月 27 日期间使用应答者驱动抽样方法在评估调查中对 11721 名吸毒者和 10005 名 MSM 进行了调查,涉及 22 个试验点。在干预阶段,综合关怀中心为 14698 名(7630 名吸毒者和 7068 名 MSM)提供了艾滋病毒检测。在主要的人群水平分析中,综合关怀中心的最近艾滋病毒检测率比常规护理点高 31%(调整后的患病率比[PR]1.31,95%置信区间[CI]0.95-1.81,p=0.09)。在干预点的调查参与者中,综合关怀中心的暴露率低于预期(吸毒者点的中位数暴露率为 40%,MSM 点为 24%)。在干预点,访问过综合关怀中心的调查参与者比未访问过的参与者更有可能报告最近的艾滋病毒检测(调整后的 PR 3.46,2.94-4.06)。
解释:尽管综合关怀中心增加了艾滋病毒检测的人数,但我们发现的低暴露率表明,在大多数城市,单一综合关怀中心的扩大规模不足以满足大量吸毒者和 MSM 人群的需求。未来的工作应该解决使用人口规模估计来指导针对关键人群的组合艾滋病毒干预措施的剂量问题。
资助:美国国立卫生研究院和 Elton John AIDS 基金会。
Int J Colorectal Dis. 2024-10-31
Open Forum Infect Dis. 2024-6-29